Premium
DIRECT‐ACTING ANTIVIRALS AS PRIMARY TREATMENT FOR HCV‐ASSOCIATED INDOLENT NON‐HODGKIN LYMPHOMAS: THE PROSPECTIVE BART STUDY OF THE FONDAZIONE ITALIANA LINFOMI
Author(s) -
Merli M.,
Rattotti S.,
Spina M.,
Re F.,
Motta M.,
Piazza F.,
Orsucci L.,
Ferreri Andrés J.M.,
Perbellini O.,
Dodero A.,
Vallisa D.,
Pulsoni A.,
Santoro A.,
Zuccaro V.,
Chimienti E.,
Russo F.,
Visco C.,
Zignego A. L.,
Marcheselli L.,
Luminari S.,
Paulli M.,
Bruno R.,
Arcaini L.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.77_2879
Subject(s) - medicine , gastroenterology , sofosbuvir , regimen , lymphoma , hepatitis c virus , lymphoplasmacytic lymphoma , ledipasvir , follicular lymphoma , ribavirin , immunology , virus , waldenstrom macroglobulinemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom